Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

NCT00734305 | Completed Phase 1 Results DMC

• 2 other identifiers: MM-121-01-100MM-121
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 3

Brief Summary

This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design to determine maximum tolerated dose/recommended Phase 2 dose.

Conditions

Advanced Solid Tumors

Keywords

cancer, solid tumors, oncology, Phase I, ErbB3, HER3; (erbB-3, HER-3)

Outcome Measures

Primary Outcomes (2)

• Objective Response Rate and Duration

  To determine the number of patients reporting an objective response using RECIST v 1.1 where a Partial Response is defined as a \>20% decrease in tumor burden from baseline and a Complete Response is defined as complete disappearance of tumor burden from baseline. Duration of response is defined as the length of time in weeks from observation of response until progression. NOTE: because no patients experienced an objective response as shown below, duration of response is not presented. No duration of response could be measured.

  Time from first dose to date of progression, with a median of 7.1 weeks

• Determine the Maximum Tolerated Dose Dependent on Reports of Dose-limiting Toxicities

  Using a 3+3 dose escalation model, the maximum tolerated dose was determined by assessing dose-limiting toxicities in each cohort from cohort 1-6. Cohort 1 began at 3.2 mg/kg IV QW and the dose escalated in separate cohorts from 6 mg/kg IV QW, 10 mg/kg IV QW, 15 mg/kg IV QW, 20 mg/kg IV QW, to the highest scheduled testing dose at 40 mg/kg one-time loading dose on cycle 1, week 1 followed by 20 mg/kg IV QW maintenance doses. If 3 patients were treated and passed the observation window, escalation to the next cohort was initiated. If a DLT was reported, 3-4 additional patients were enrolled and observed. If a DLT was observed in the expanded cohort, this dose was considered to be the maximum tolerated dose. The maximum tolerated dose was defined at the cohort in which two dose-limiting toxicities were observed, or as the highest target dose tested in the absence of DLTs. The determined MTD was considered the Recommended Phase 2 Dose and was used to open the expansion cohort.

  From date of first dose to 30 days after termination, the longest 47 weeks

Secondary Outcomes (3)

• To Describe the Dose-limiting Toxicity of MM-121 as a Monotherapy

  From date of first dose to 30 days after termination, the longest 47 weeks

• To Determine the Pharmacokinetic and Immunogenicity Parameters of MM-121

  At Cycle 1, Week 1 pre-treatment, at the end of the infusion, and 2, 4, 8, 24, 48 and 72 hours after starting the infusion; pre-dose collections on Cycle 1, Week 2 and Cycle 2, Week 1 for all patients

• To Determine the Pharmacokinetic Parameters of MM-121

  At Cycle 1, Week 1 pre-treatment, at the end of the infusion, and 2, 4, 8, 24, 48 and 72 hours after starting the infusion; pre-dose collections on Cycle 1, Week 2 and Cycle 2, Week 1 for all patients

Study Arms (1)

Dose Escalation

EXPERIMENTAL

Cohorts of escalating doses of MM-121 administered IV QW to determine MTD or RP2D + expansion cohort at MTD/RP2D

Drug: MM-121

Interventions

MM-121 DRUG

Dose escalation Frequency - once weekly

Also known as: Seribantumab, SAR256212

Dose Escalation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have histologically or cytologically confirmed advanced solid tumors that have recurred or progressed following standard therapy, or that have not responded to standard therapy, or for which there is no standard therapy, or who are not candidates for standard therapy
• Patients must be \> 18 years of age
• Patients or their legal representatives must be able to understand and sign an informed consent form
• Patients must have evaluable or measurable tumor(s)
• Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy. Up to CTCAE Grade 1 is acceptable for patients with known peripheral neuropathy.
• Women of childbearing potential as well as fertile men and their partners must agree to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-121 (an effective form of contraception is an oral contraceptive or a double barrier method)
• In addition, patients to be enrolled the Expansion Cohort must have/be:
• Advanced/metastatic breast cancer with histological/cytological documentation of ER-, PR-, Her2/neu non-over-expressing breast cancer (triple negative breast cancer); OR,
• Patients must have advanced/metastatic breast cancer with histologically or cytologically confirmed ER+ and/or PR+, Her2/neu non-over-expxressing OR,
• Patients must have advanced/metastatic histological confirmation of epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer; OR,
• Additional tumor types such as metastatic colorectal, advanced non small cell lung cancer, and others may be considered on a per-patient basis
• Tumor tissue amenable to biopsy
• Platelet counts, partial thromboplastin time (PTT) and international normalized ratio (INR) within normal limits.
• Willing to undergo tumor biopsy twice (once before and once after treatment with MM-121)
• Blocks of archived formalin-fixed, paraffin-embedded, unstained tumor tissue available for submission. Patients with no available archived tumor tissue available must receive Sponsor approval prior to enrollment.

You may not qualify if:

• Patients for whom potentially curative antineoplastic therapy is available
• Patients who are pregnant or lactating
• Patients with an active infection or with an unexplained fever \> 38.5°C during screening visits or on the first scheduled day of dosing. (At the discretion of the investigator, patients with tumor fever may be enrolled.)
• Patients with untreated and/or symptomatic CNS malignancies (primary or metastatic); patients with CNS metastases who have undergone surgery or radiotherapy, whose disease is stable, and who have been on a stable dose of corticosteroids for at least 2 weeks prior to the first scheduled day of dosing will be eligible for the trial
• NYHA Class III or IV congestive heart failure or LVEF \< 55%
• Known HIV, hepatitis B or C (active, previously treated or both)

Sponsors & Collaborators

• Merrimack Pharmaceuticals: lead
• Sanofi: collaborator

Study Sites (3)

Dana-Farber Cancer Institute

Boston, Massachusetts, 02115-6084, United States

Location

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States

Location

The Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States

Location

Related Publications (1)

• Denlinger CS, Keedy VL, Moyo V, MacBeath G, Shapiro GI. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 2021 Dec;39(6):1604-1612. doi: 10.1007/s10637-021-01145-y. Epub 2021 Jul 11.

  PMID: 34250553 DERIVED

MeSH Terms

Conditions

Neoplasms; Lethal Congenital Contracture Syndrome 2

Interventions

seribantumab

Results Point of Contact

• Title: Clinical Trial Manager
• Organization: Merrimack Pharmaceuticals, Inc.

smathews@merrimack.com

617-441-1000

Study Officials

• Crystal Denlinger, MD

  Fox Chase Cancer Center

  PRINCIPAL INVESTIGATOR

• Kwok Kin Wong, MD

  Dana-Farber Cancer Institute

  PRINCIPAL INVESTIGATOR

• Keedy L Vicki, MD

  Vanderbilt University Medical Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: LTE60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 12, 2008
• First Posted: August 14, 2008
• Study Start: July 1, 2008
• Primary Completion: May 1, 2010
• Study Completion: September 1, 2013
• Last Updated: September 1, 2016
• Results First Posted: September 1, 2016

Record last verified: 2016-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)